HSPA9 and cancer: As MKT-077 is a cancer cell-selective small molecule inhibitor, our present initiative based on the utilization of the GRP75 targeting-induced G1-phase-privileged CME route is a simple approach to enhance the delivery efficiency of such kind of nanoparticles.